1,898 results on '"Meijer, Gerrit A"'
Search Results
2. Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers.
3. CIBRA identifies genomic alterations with a system-wide impact on tumor biology
4. Cancer treatment monitoring using cell-free DNA fragmentomes
5. Stool-Based Testing for Post-Polypectomy Colorectal Cancer Surveillance Safely Reduces Colonoscopies: The MOCCAS Study
6. Combining Colonoscopy With Fecal Immunochemical Test Can Improve Current Familial Colorectal Cancer Colonoscopy Surveillance: A Modelling Study
7. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice
8. High Prevalence of Chromosomal Rearrangements and LINE Retrotranspositions Detected in Formalin-Fixed, Paraffin-Embedded Colorectal Cancer Tissue
9. The multitarget faecal immunochemical test for improving stool-based colorectal cancer screening programmes: a Dutch population-based, paired-design, intervention study
10. Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics
11. Initial Impact of National CRC Screening on Incidence and Advanced Colorectal Cancer
12. A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice
13. Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors
14. Tumour break load is a biologically relevant feature of genomic instability with prognostic value in colorectal cancer
15. Guidance for setting international standards on reporting longitudinal adherence to stool-based colorectal cancer screening
16. Overexpression of the miR-17-92 cluster in colorectal adenoma organoids causes a carcinoma-like gene expression signature
17. Faecal Volatile Organic Compounds to Detect Colorectal Neoplasia in Lynch Syndrome—A Prospective Longitudinal Multicentre Study.
18. Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested case–control study
19. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study
20. Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN)
21. High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence
22. KCNQ1 and lymphovascular invasion are key features in a prognostic classifier for stage II and III colon cancer
23. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases
24. Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer
25. Using discrete element method (DEM) to create a cone penetration test (CPT)-based method to estimate the installation requirements of rotary-installed piles in sand
26. A scenario‐drafting study to explore potential future implementation pathways of circulating tumor DNA testing in oncology.
27. The influence of earthworks construction on porewater pressures in clays and mudstones of the Lias Group.
28. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer
29. New methods for in situ measurement of mechanical root-reinforcement on slopes
30. Genetic Profiling of Colorectal Carcinomas of Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease
31. Biomarkers for clinical benefit to immune checkpoint blockade treatment in NSCLC
32. Improved detection of colibactin-induced mutations by genotoxic E. coli in organoids and colorectal cancer
33. Polyketide synthase positive Escherichia coli one-time measurement in stool is not informative of colorectal cancer risk in a screening setting
34. Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer
35. Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer
36. CIBRA identifies genomic alterations with a system-wide impact on tumor biology
37. Post-colonoscopy colorectal cancers in a national FIT-based CRC screening program
38. The landscape of genomic copy number alterations in colorectal cancer and their consequences on gene expression levels and disease outcome
39. Reply to R. Pham et al
40. Genome Nexus: A Comprehensive Resource for the Annotation and Interpretation of Genomic Variants in Cancer
41. Polyketide synthase positive Escherichia coli one‐time measurement in stool is not informative of colorectal cancer risk in a screening setting
42. Aberrant PRDM2 methylation as an early event in serrated lesions destined to evolve into microsatellite‐instable colorectal cancers
43. Supplementary Fig. S2 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
44. Supplementary Table S5 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
45. Data from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
46. Identification of DNA methylation markers for early detection of CRC indicates a role for nervous system-related genes in CRC
47. Detection and characterization of lung cancer using cell-free DNA fragmentomes
48. Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study
49. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly.
50. Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.